title: Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
abstract: BACKGROUND
  Gastro-oesophageal reflux disease (GERD) patients on proton pump inhibitors before breakfast or dinner have acid recovery at night. Bedtime immediate-release omeprazole (IR-OME) demonstrated better control of nocturnal pH than pantoprazole before dinner.
  
  
  OBJECTIVE
  To compare repeated once daily bedtime dosing of IR-OME, lansoprazole and esomeprazole on nocturnal gastric acidity.
  
  
  METHODS
  Open-label, randomized, crossover study enrolling 54 patients with nocturnal GERD symptoms comparing IR-OME, lansoprazole and esomeprazole at steady state for nocturnal acid breakthrough (NAB), percentage of time with gastric pH > 4 and median gastric pH.
  
  
  RESULTS
  Onset of nocturnal acid control with IR-OME was rapid. During the first half of the night, percentage of time with gastric pH > 4 and median gastric pH were significantly higher after IR-OME compared to esomeprazole or lansoprazole (P < 0.001, both comparisons). Over the 8-h night-time period, acid control with IR-OME was significantly better than lansoprazole (P < 0.001), and comparable to esomeprazole. IR-OME reduced NAB compared with esomeprazole and lansoprazole (61% vs. 92% and 92%; P < 0.001, both comparisons).
  
  
  CONCLUSIONS
  Bedtime IR-OME provided more rapid control of night-time gastric pH and decreased NAB compared with esomeprazole and lansoprazole. Nocturnal acid control with IR-OME was superior to lansoprazole and comparable to esomeprazole. Bedtime dosing with IR-OME may be effective for patients with night-time heartburn.
authors.affiliation: Albert Einstein Medical Center, Philadelphia, PA 19141-3018, USA. katzp@einstein.edu
authors.forename: P O
authors.initials: PO
authors.lastname: Katz
authors.forename: F K
authors.initials: FK
authors.lastname: Koch
authors.forename: E D
authors.initials: ED
authors.lastname: Ballard
authors.forename: R G
authors.initials: RG
authors.lastname: Bagin
authors.forename: T C
authors.initials: TC
authors.lastname: Gautille
authors.forename: G C
authors.initials: GC
authors.lastname: Checani
authors.forename: D L
authors.initials: DL
authors.lastname: Hogan
authors.forename: V S V
authors.initials: VS
authors.lastname: Pratha
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000863:Antacids / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D064098:Esomeprazole; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000863:Antacids; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D009853:Omeprazole; D064098:Esomeprazole